vTv Therapeutics Inc
NASDAQ:VTVT
vTv Therapeutics Inc
NASDAQ:VTVT
Price:
36
USD
0.08%
Market Closed
Market Cap:
$141.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
US |
|
C
|
Cardiovascular Systems Inc
F:R7Y1
|
US |
|
H
|
Hengdian Group Tospo Lighting Co Ltd
SSE:603303
|
CN |
|
Duke Exploration Ltd
ASX:DEX
|
AU |
|
Alue Co Ltd
TSE:7043
|
JP |
|
Fortinet Inc
NASDAQ:FTNT
|
US |
|
T
|
Techbond Group Bhd
KLSE:TECHBND
|
MY |
|
ORG Technology Co Ltd
SZSE:002701
|
CN |
|
N
|
Nichiwa Sangyo Co Ltd
TSE:2055
|
JP |
|
Morganite Crucible (India) Ltd
BSE:523160
|
IN |
|
J
|
Jastrzebska Spolka Weglowa SA
WSE:JSW
|
PL |
|
Riot Blockchain Inc
NASDAQ:RIOT
|
US |
|
Jiangsu Zitian Media Technology Co Ltd
SZSE:300280
|
CN |
|
Artemis Gold Inc
XTSX:ARTG
|
CA |
Relative Value
The Relative Value of one
VTVT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 36 USD,
vTv Therapeutics Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
VTVT Relative Value
HIDDEN
Multiples Across Competitors
VTVT Competitors Multiples
vTv Therapeutics Inc Competitors
vTv Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
141.8m USD | 0 | -5.3 | -1.6 | -1.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.2 | 12.6 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.1 | 131.9 | 73.8 | 82 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
